Nonclinical Sciences & Technology

Aug 18

Therapeutic Antibodies Series 2026

  • Accelerating antibody discovery using advanced screening technologies
  • Enhancing performance through engineeSeiring strategies such as bispecifics and ADCs
  • Key considerations for specificity, safety and developability
  • Best practices for scalable manufacturing and clinical translation

Register here

 

Aug 13

Mouse Models Shaping Antiviral Vaccine Development

  • C57BL/6 and BALB/c inbred strains as foundational models in vaccine testing and immunogenicity
  • Genetically engineered mice expressing humanized receptors or HLA alleles that improve viral entry and antigen presentation
  • Humanized immune system models, such as immunodeficient NSG mice engrafted with human PBMCs, which enable assessment of human-specific immune responses in situ that inform vaccination strategies.
  • Future directions in xenograft model development that will provide further insight into tissue-specific human immune responses to this respiratory pathogen
  • Register here

 

Aug 18

Choosing the right study for developmental and reproductive safety testing

  • The role of DART studies in nonclinical safety assessment
  • Key differences between the major types of DART studies and when each is appropriate
  • Factors that influence study selection and design
  • The role of juvenile and multigeneration studies in evaluating developmental risk
  • How study design supports regulatory decision-making aSend efficient drug development

Register here

Aug 26-27

Advances in immuno-oncology

This virtual two-day symposium will gather researchers to present the latest breakthroughs in cancer immunology.

  • Tumor–immune interactions and the tumor microenvironment
  • Emerging approaches in cancer immunotherapy and anti-tumor immunity
  • Novel therapeutic strategies for targeting cancer and metastatic disease
  • Advances in translational oncology and mechanisms of therapeutic response

Register here

 

Sept 1

Building the Data Foundation for AI-Native Small Molecule R&D   (Benchling)

  • Understand why isolated reaction records limit scientific reuse and what structured data capture enables across research teams, computational workflows, and AI-assisted discovery
  • Learn how connecting chemistry and biology on a shared platform accelerates cross-modality programs such as antibody-drug conjugates and hybrid therapeutics
  • Identify practical steps R&D teams can take now to build an AI-ready chemistry data foundation before data silos compound

Register here

 

Sept 16

Overcoming Immunotherapy Resistance in Liver Cancer

  • Mechanisms of immune checkpoint inhibitor resistance
  • PD-L1 regulation and stability in hepatocellular carcinoma
  • Donor-specific variability in immunotherapy response
  • Combination strategies targeting AURKA and PD-L1
  • The PVR/Nectin-2 immune checkpoint pathway
  • NK cell and T cell-mediated
  • Precision immunotherapy for liver cancer

Register here

 

Sept 17

Understanding How the Tumor Microenvironment Reshapes Anti-Tumor Immunity

  • How the tumor microenvironment reshapes infiltrating immune cells
  • In vivo models for tracking immune cell migration and persistence
  • Mechanisms regulating anti-tumor immunity
  • Therapeutic interventions that alter immune cell function
  • Rational development of combination immunotherapies

Register here

 

Sept 18

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Register here

 

Oct 7

Rigorous by Design: Strengthening Research That Involves Animals

Register here

Business Development

Aug 25 

Developing a Product Portfolio: Virtual Outsourcing Facility Discussion

Business Development Webinar by Regan Udall Foundation

Join our discussion with outsourcing facility executives and a group purchasing organization about developing a portfolio, including how to maintain and evolve a portfolio and how customer relationships and operational capacity factor into decision making.

Register here

 

------------------------------------------------------------

 

 

---------------------------------------------------------------------------------------------------------------------------------------------------------------------